Financial Results for the quarter and year ended March 31, 2026
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs reported strong full-year results for FY2026 ended March 31. Standalone total income jumped 58.7% to ₹2,40,339 lakhs from ₹1,51,508 lakhs, driven by robust pharmaceutical business growth. Profit after tax grew 27.6% to ₹4,055 lakhs from ₹3,184 lakhs. On a consolidated basis (including 3 subsidiaries and 2 step-down subsidiaries), total income stood at ₹2,40,339 lakhs with PAT at ₹4,055 lakhs and EPS of ₹2.03. The Board also re-appointed the Cost Auditor and Internal Auditor for FY27, and reconstituted the Risk Management Committee adding one more member. Auditors Gokhale & Sathe issued clean un-modified opinions on both standalone and consolidated results.
Strong topline growth of ~59% is positive but the PAT growth of ~28% lagged revenue growth, suggesting cost pressures or margin compression. The clean audit opinions and positive operating cash flow of ₹25,414 lakhs (standalone) are reassuring for shareholders.